Kiora Pharmaceuticals (NASDAQ:KPRX) Posts Earnings Results, Beats Expectations By $0.13 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) issued its quarterly earnings data on Friday. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Stock Up 3.1%

Shares of Kiora Pharmaceuticals stock traded up $0.08 during midday trading on Friday, hitting $2.64. The company had a trading volume of 23,543 shares, compared to its average volume of 22,446. The company has a fifty day simple moving average of $2.57 and a 200 day simple moving average of $2.37. The stock has a market cap of $11.70 million, a price-to-earnings ratio of -0.97 and a beta of -0.38. Kiora Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $3.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in shares of Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after buying an additional 8,800 shares during the period. Two Sigma Investments LP purchased a new stake in Kiora Pharmaceuticals in the third quarter valued at approximately $33,000. Citadel Advisors LLC purchased a new position in Kiora Pharmaceuticals during the 3rd quarter worth approximately $125,000. DRW Securities LLC raised its position in Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after buying an additional 73,417 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Kiora Pharmaceuticals in the 4th quarter valued at $152,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.